Long-term outcomes of patients with 10 or more colorectal liver metastases by Allard, M.A. (M. A.) et al.
Long-term outcomes of patients with 10 or
more colorectal liver metastases
M A Allard1, R Adam*,1, F Giuliante2, R Lapointe3, C Hubert4, J N M Ijzermans5, D F Mirza6, D Elias7,
C Laurent8, T Gruenberger9, G Poston10, C Letoublon11, H Isoniemi12, V Lucidi13, I Popescu14 and J Figueras15
1Centre He´pato-biliaire, APHP Paul Brousse Hospital, Univ. Paris-Sud, INSERM U 935, Villejuif, France; 2Department of HBP
Surgery, Catholic University of the Sacred Heart School of Medicine, Rome, Italy; 3Department of HBP Surgery, University of
Montreal, Montreal, QC, Canada; 4Department of HBP Surgery, Cliniques Universitaires Saint-Luc, Universite´ Catholique de
Louvain, Louvain, Belgium; 5Department of HBP surgery, Erasmus University Medical Center, Rotterdam, The Netherlands;
6Department of HBP surgery, University Hospital Birmingham, Birmingham, UK; 7Department of Oncological Surgery, Gustave
Roussy, Villejuif, France; 8Department of Surgery, Saint Andre´ Hospital, Bordeaux, France; 9Department of Surgery, Medical
University of Vienna, Vienna, Austria; 10Department of Surgery, University Hospital Aintree, Liverpool, UK; 11Department of
Surgery, University Joseph Fournier, Grenoble, France; 12Department of Liver Surgery and Transplantation, Helsinki University,
Helsinki, Finland; 13Department of Surgery, Hospital Erasme, Universite´ Libre de Bruxelles, Brussels, Belgium; 14Department of
Surgery and Transplantation, Fundeni Clinical Institute, Bucharest, Romania and 15Department of Surgery, Dr Josep Trueta
Hospital, Girona, Spain
Background: Although the number of colorectal liver metastases (CLM) is decreasingly considered as a contraindication to
surgery, patients with 10 CLM or more are often denied liver surgery. This study aimed to evaluate the outcome after liver surgery
and to identify prognostic factors of survival in such patients.
Methods: The study population consisted of a multicentre cohort of patients with CLM (N¼ 12 406) operated on, with intention to
resect, from January 2005–June 2013 and whose data were prospectively collected in the LiverMetSurvey registry.
Results: Overall, the group X10 CLM (N¼ 529, 4.3%) experienced a 5-year overall survival (OS) of 30%. A macroscopically
complete (R0/R1) resection (72.8% of patients) was associated with a 3- and 5-year OS of 61% and 39% vs 29% and 5% for R2/no
resection patients (Po0.0001). At multivariate analysis, R0/R1 resection emerged as the strongest favourable factor of OS (HR 0.35
(0.26–0.48)). Other independent favourable factors were as follows: maximal tumour size o40mm (HR 0.67 (0.49–0.92)); age o60
years (HR 0.66 (0.50–0.88)); preoperative MRI (HR 0.65 (0.47–0.89)); and adjuvant chemotherapy (HR 0.73 (0.55–0.98)). The model
showed that 5-year OS rates of 30% was possible provided R0/R1 resection associated with at least an additional favourable factor.
Conclusions: Liver resection might provide long-term survival in patients with X10 CLM staged with preoperative MRI, provided
R0/R1 resection followed by adjuvant therapy. A validation of these results in another cohort is needed.
In the past surgical series of colorectal liver metastases (CLM)
published (Wilson and Adson, 1976; Ekberg et al, 1986) in the
1970s–1980s, the presence of more than three CLM was considered
as a contraindication for resection. Since then, CLM management
has considerably evolved (Adam et al, 2012). Innovations in
surgical techniques have pushed the boundaries of resectability
while the introduction of efficient cytotoxic agents in association
with targeted therapies (Cutsem et al, 2009; Kabbinavar et al, 2009)
have markedly increased tumour response rate and chance for
surgery in patients with unresectable disease at presentation
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(Adam et al, 2004a, 2009). As a consequence, the oncological
dogma of ‘no more than three CLM’ has been progressively
challenged. However, the cut-off number for which surgery does
not provide any benefit is still unknown and there is currently very
few data regarding the oncological results of liver resection
performed in patients exhibiting a high number of CLM. We only
found studies that focused on outcome of patients exhibiting more
than four to eight CLM (Ferrero et al, 2004; Elias et al, 2005;
Tamandl et al, 2007; Zakaria et al, 2007; Rees et al, 2008; Vigano`
et al, 2015) with too limited series to draw practical conclusions
(Smith and McCall, 2009). As the majority of patients with a larger
number of CLM are exclusively treated by chemotherapy, results of
surgery are lacking.
On the other hand, chemotherapy has significantly increased its
efficacy in recent years, but long-term survival still remains
anecdotal (Van Cutsem et al, 2011; Cremolini et al, 2015).
This prompts us to investigate the outcome of patients operated
on for a large number of CLM. As there is no established cut-off
defining what a ‘large’ number of CLM is, we choose the cut-off of
10 CLM by analogy with the EORTC randomised trial in which 10
CLM was the limit for RFA indication. Beyond such cut-off,
medical oncologists and surgeons usually consider that there is no
more place for surgery.
The use of a large multicentric cohort of patients operated on
for CLM allows us to obtain a critical number of patients operated
on for 10 CLM or more, required to achieve this analysis.
Our objectives were the following ones: (i) to report the results
of patients operated on for 10 CLM or more by comparing to that
observed in patients with fewer CLM; and (ii) to identify within
this group of patients, the factors associated with a real survival
benefit.
MATERIALS AND METHODS
Study population
LiverMetSurvey registry. We used the multicentric cohort of
patients operated on for CLM between January 2005 and June
2013, and whose data were prospectively registered in the
LiverMetSurvey international registry. LiverMetSurvey (http://
www.livermetsurvey.org/) is an international database that pro-
spectively collects clinical and pathological data of patients
undergoing surgery for CLM (Adam et al, 2010; Andres et al,
2012; Vigano` et al, 2012). This register currently involves 485
centres across a total of 59 countries. Data are prospectively
entered by using an online questionnaire, which includes
demographic and pathologic variables as well as informations
concerning the type, duration and effects of preoperative
treatment, the surgical procedure, the timing, location and
treatment of recurrence, as well as the post-operative and long-
term outcome. Data are regularly updated by each centre, and a
quality control of the data is performed by a data manager who
sends twice a year to each contributing centre a personalised
information, concerning the items to complete or to update for
each patient of the centre cohort.
Selection of the study population. Our initial study population
consists of all consecutive patients registered in the LiverMetSurvey
during the study period with available number of CLM on imaging
studies at diagnosis (CT or MRI) of the liver disease. The resulting
cohort consists on a total of 12 406 patients. Of them, we
specifically focused on patients exhibiting 10 CLM or more
(N¼ 529).
All patients included in this study were operated on for CLM
with an intention to resect on a curative intent. Some of them were
not resected due to intraoperative discovery of extrahepatic disease
or to more extended liver disease contraindicating radical surgery.
In the remaining patients, resection was classified as R0, R1 or R2
as defined below.
Definition of the type of resection. R0 resection was defined by a
macroscopically complete removal of the totality of hepatic
metastases with X1mm-free margins. R1 resection referred to
macroscopically complete removal of lesions with at least one
positive margin (o1mm) or the use of local ablation (radio-
frequency and microwave ablation). R2 resection referred to a
macroscopically incomplete resection.
Study design. This study was divided into three steps.
Step 1: comparisons of the group of patients with X10 CLM
with two other groups: 1–3 CLM and 4–9 CLM.
Step 2: identification of the factors affecting overall survival
(OS) in the group X10 CLM.
Step 3: calculation of survival probabilities in patients withX10
CLM according to a predictive model.
Statistical analysis
Comparisons. Comparisons between categorical data and contin-
uous data were done by using the w2-test and ANOVA test,
respectively.
Survival analysis. Continuous variables were transformed into
categorical data by using the roughly rounded values of the mean
as cut-off for more readability. The survival probabilities were
calculated according to Kaplan–Meier method and survival plots
were compared with the log rank test. For OS, time was calculated
from the date of CLM diagnosis to the date of last news. For
‘primary’ DFS, time was calculated from the time of resection to
the date of first relapse or death. Incomplete resection was
considered as a relapse at time 0. In case of multistep procedures
(i.e., two-stage hepatic resection), the DFS was calculated from the
date of last resection. ‘Secondary’ DFS was calculated for patients
who underwent R0/R1 liver resection. Time for secondary DFS was
the period between the first hepatectomy and the date of the last
relapse that could not be treated curative intent. Relapse was
defined as the occurrence of new metastatic localisation.
Multiple imputations. To avoid biased estimates (Janssen et al,
2010), missing data were imputed (N¼ 10). Variables with a
proportion of missing values 430% were not selected for
imputation and not considered for analysis. Imputations were
generated by using the predictive mean-matching method. Then,
the plausibility of imputed data was checked.
Cox proportional hazards model. Variables with P–values o0.15
at univariate analysis were entered into a Cox proportional hazard
model for multivariate analysis. Continuous variables were
transformed into binary variables by using their mean value. This
makes scoring system easier to use. The final selection of variables
retained in the final model used the minimal Akaike Information
Criterion approach. The proportional hazards assumption for each
covariate and for the entire model was checked by using
Schoenfeld’s residuals.
Then, the coefficients obtained for each data set were combined
to estimate the final regression coefficient according to Rubin’s
rule. (Rubin, 1987).
Prediction of survival probabilities. For each data set, we
calculated the survival probabilities predicted by the final Cox
model according to the different combination of factors. We then
obtained the average survival probabilities for each situation across
data sets.
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The analysis was done using the statistical programming
language R, version 3.1.1, the ggplot2, rms and mice packages.
RESULTS
Characteristics of patients with 10 CLM or more compared to
groups: 1–3 CLM and 4–9 CLM. As expected, the three groups
(1–3 CLM, 4–9 CLM and X10 CLM) exhibited major differences
with regard to characteristics of patients, of primary tumour
features, of metastatic disease and perioperative management.
Comparisons are detailed in Table 1. Briefly, the number of CLM
was associated with younger patients and lower proportion of
rectal cancers. It also correlates with an increased maximal tumour
size, an increased proportion of bilobar distribution, of synchro-
nous CLM, of initial non-resectability and of preoperative
chemotherapy. The proportion of R2 resection/no resection was
the highest in theX10 CLM group (27.2% vs 14.7% and 5% in the
4–9 CLM group and 1–3 CLM group, respectively; Po0.0001).
Perioperative complications and mortality. The 90-day mortality
observed in the X10 CLM group was significantly higher (4.8%).
Severe morbidity (grade III–IV) was comparable to that of the 3–9
CLM group but higher than the group of 1–3 CLM. There was a
significant increase in the risk of 90-day mortality with the age, for
each subgroup of CLM number (Supplementary File 1).
Overall survival and disease-free survival. The median follow-up
from diagnosis was 29.4 months. As expected, we observed a
significant decrease in OS when comparing 1–3 CLM group vs 4–9
CLM group and 4–9 CLM group vsX10 CLM group (Figure 1A).
Accordingly, the 3- and 5-year OS rates were 70 and 49% in the
1–3 CLM group, 60 and 39% in the 4–9 CLM group and 52 and
30% in the X10 CLM group. Similar impact was observed for
primary DFS (Figure 1B). Indeed, 3-year primary DFS was 38%,
20% and 16% in patients with 1–3 CLM, 4–9 CLM andX10 CLM,
respectively (Po0.0001).
Similar findings were observed when OS probabilities were
calculated from the date of resection. The Kaplan–Meier OS curves
are given in Supplementary File 2.
Patients with X10 CLM
Proportion. Overall, the group X10 CLM accounted for 4.3% of
the entire study population. We observed a significant increase in
the proportion of patients operated over the study period. The
group X10 CLM represented 3.8% of the cohort during the first
part of the study period (January 2005–December 2008) vs 4.8%
(P¼ 0.03) in the most recent period (January 2009—June 2013).
Resectability. Not surprisingly, the majority of patients (68.4%)
with 10 CLM or more received preoperative chemotherapy, and
resection was undertaken after a control of the disease (response or
stabilisation) in 96.3% of them.
The resectability (R0/R1) rate was 72.8%. Among resected
patients, the proportion of R0 resection and R1 resection
(including use of local ablation) were 43.1% and 56.9%,
respectively.
Overall, 27.2% of patients with X10 CLM underwent either (i)
R2 resection: failure of planned two-stage hepatectomy (N¼ 62,
48.1%) or (ii) no resection at all because of intraoperative findings
of unresectable CLM, and/or extrahepatic disease (lymph node,
carcinomatosis (N¼ 67, 51.9%)).
Table 1. Baseline characteristics of each group
1–3 CLM 4–9 CLM X10 CLM
N¼9643 N¼2234 N¼529 P
Variables No. % No. % No. %
Sex: male 5932 61.5 1400 62.7 315 59.5 0.36
Mean age (±s.d.), years 63.3 (±11) 60.1 (±11) 58.5 (±10) o0.0001
Primary tumour
Location: rectum 3092 32.8 737 33.8 133 25.8 0.002
Stage T3–T4 7358 87.8 1741 89.7 396 90.0 0.03
Stage N positive 5253 63.1 1328 69.6 319 74.4 o0.0001
CLM characteristics
Mean number of CLM (±s.d.) 1.6 (±0.7) 5.3 (±1.4) 13.4 (±4) o0.0001
Mean maximum tumour size (±s.d.), mm 37.6 (±28) 38.9 (±28) 44.5 (±35) o0.0001
Mean CEA level, ngml1 119.4 (±80) 123.4 (±79) 137.1 (±77) o0.0001
Distribution: bilobar 2141 22.4 1736 78.6 497 94.3 o0.0001
Initially resectable 7774 88.2 1283 62.6 163 32.1 o0.0001
Time of occurrence: synchronous 4650 48.6 1571 71.1 458 87.1 o0.0001
Concomittant extrahepatic disease 916 9.7 238 10.9 70 13.5 0.008
Perioperative management
Preop. MRI 3497 39.7 951 45.9 213 44.6 0.04
Preop. chemotherapy 3391 37.1 1329 61.9 353 68.4 o0.0001
Preop. targeted therapy 1277 38.6 629 47.9 208 59.3 o0.0001
Progression while on chemotherapya 261 7.7 83 6.2 13 3.7 0.002
Portal vein embolisation 561 6.1 424 19.5 201 39.1 o0.0001
Postop. chemotherapy 3824 54.2 963 56.4 191 51.3 0.12
Postop. targeted therapy 752 20.3 309 32.7 83 43.9 o0.0001
Early outcomes
R0/R1 liver resection 8742 95.0 1790 85.3 346 72.8 o0.0001
90-day mortality 200 2.1 76 3.4 25 4.8 0.0001
Grade III–IV morbidityb 1389 16.8 363 19.0 81 18.7 0.05
Abbreviations: CEA¼ carcinoembryonic antigen; CLM¼ colorectal liver metastases; MRI¼magnetic resonance imaging; Postop.¼postoperative; Preop.¼preoperative.
aCalculations were made based on the number of patients who received preoperaive chemotherapy.
bDindo–Clavien classification.
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Identification of the prognostic factors for OS in patients with
X10 CLM
Univariate analysis. We did not observe any difference in terms
of OS between R0 patients and R1/combined RFA patients (3- and
5-year OS rates of 73 and 45% vs 60 and 44%; P¼ 0.72). Patients
with R2 resection achieved similar outcomes than those without
any resection (3- and 5-year OS rates of 29 and 6% vs 28 and 0%
for R2 resection and no resection group; P¼ 0.77). However, the 3-
and 5-year OS rates were much higher for combined R0/R1
resection groups compared to R2/no resection groups (61 and 39%
for R0/R1 resection group vs 29 and 5% in the group with R2/no
resection at 3 and 5 years, respectively, Po0.0001; Figure 2A).
Then, we decided to perform the analysis by combining R0/R1
resection and R2/no resection groups.
Results of univariate analysis in original set and imputed data
are provided in Table 2. Others factors with a P-valueo0.15 were
as follows: age X60 years; maximal tumour size X40mm; a
preoperative MRI; preoperative chemotherapy; and adjuvant
chemotherapy. Of note, the number of CLM in the group of
patients with X10 CLM had no influence on outcome (HR: 1.0
(0.97–1.03); P¼ 0.92).
Multivariate analysis. The five factors that remained in the Cox
model in all data sets were the following: type of resection (R0/R1);
age X60 years; adjuvant chemotherapy; maximal tumour size
X40mm; and preoperative MRI. The C-index ranged from 0.68 to
0.71 across imputed data sets.
The pooled estimates of the factors, retained in the final model,
are as follows: R0/R1 resection (HR 0.35 (0.26–0.48); Po0.0001);
preoperative MRI (HR 0.65 (0.47–0.89); P¼ 0.007); adjuvant
chemotherapy (HR 0.73 (0.55–0.98); P¼ 0.04); maximal tumour
size X40mm (HR 1.49 (1.09–2.03); P¼ 0.02); and age X60 years
(HR 1.51 (1.13–2.00), P¼ 0.005; Table 3).
Recurrence after R0/R1 liver resection. The primary DFS was
similar between the group R0 resection and that with R1 resection/
RFA use (31 and 8% vs 22 and 6% at 3 and 5 years; P¼ 0.56).
Of the 346 patients who underwent R0/R1 resection, 258
(74.6%) had developed a recurrence at last follow-up. The 3- and 5-
year primary DFS rates were 23% and 7%, respectively. Hepatic
recurrence and extrahepatic recurrence were surgically treated in
49 (19%) and 14 patients (5.4%), respectively. The secondary DFS
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Figure 1. Survival according to the number of CLM. (A) Kaplan–
Meier overall survival curves according to the number of CLM.
(B) Kaplan–Meier primary disease-free survival according to the number
of CLM.
1.0
83%
B
57%
45%
22%
P<0.0001
0.8
0.6
0.4
0.2
0.0
0
O
ve
ra
ll 
su
rv
iva
l
195 152 91
49
49
30
23
19 10
9 3
75963
12 24
Time from diagnosis (months)
36 48
R0/R1 resection
R2/no resection
60 72
R0/R1 resection
Repeat surgery
A
R2/no resection
No repeat surgery
P<0.0001
1.0
0.8
0.6
0.4
0.2
0.0
O
ve
ra
ll 
su
rv
iva
l
No repeat surgery
Repeat surgery
129
346
88 41 17 4
50
1
24 1294168265
Time from diagnosis (months)
61%
39%29%
5%
0 12 24 36 48 60 72
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overall survival curves of patients who relapsed after R1/R0 resection
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rates (taking into account the impact of repeat surgery) at 3 and 5
years were 42% and 31%, respectively. The OS of patients who
underwent repeat surgery was significantly better than that of
patients whom recurrence was managed by exclusive chemother-
apy (83 and 57% vs 45 and 22% at 3 and 5 years; Po0.0001;
Figure 2B).
Survival probabilities according to the distribution of prog-
nostic factors. We calculated the average survival probabilities
across imputed data sets in patients who underwent R0/R1
resection according to each cofactor association (Table 4).
Thus, patients with all additional four favourable factors, the 3-
and 5-year OS rates were 82% and 69%, respectively. The OS
Table 2. Univariate analysis for overall survival in patients with X10 CLM (original data set)
Variables 3-year OS (%) 5-year OS (%) MS (months) P
Patient
Sex
Female 46 32 34 0.22
Male 56 29 40
Age (years)
o60 58 36 46 0.001
X60 44 21 35
Primary tumour
Location
Colon 53 31 38 0.35
Rectum 48 25 34
Stage T
T0–T2 63 26 54 0.16
T3–T4 50 29 36
Lymph node
N0 57 35 44 0.44
Nþ 51 27 37
CLM characteristics
Maximum tumour size
o40mm 60 34 42 0.005
X40mm 43 26 32
CEA
o100 ngml 1 56 29 42 0.02
X100 ngml 1 37 16 32
CLM distribution
Unilobar 53 30 38 0.67
Bilobar 43 43 34
Initial resectability
Unresectable 51 30 37 0.98
Resectable 52 30 37
CLM occurrence
Metachronous 48 36 34 0.22
Synchronous 53 30 38
Extrahep. disease
N 52 31 37 0.09
Y 47 22 34
Management
Preop. MRI
N 44 27 33 0.0009
Y 66 38 47
Preop. chemotherapy
N 43 27 31 0.01
Y 57 31 39
Preop. targeted therapy
N 51 23 36 0.12
Y 61 41 42
Response to preop. chemotherapy
N 54 28 38 0.42
Y 66 53 69
Portal vein embolisation
N 49 35 36 0.81
Y 56 27 40
Adjuvant chemotherapy
N 48 30 34 0.08
Y 55 31 40
Postop. targeted therapy
N 54 34 40 0.97
Y 58 27 42
Quality of resection
R2/no resection 29 5 27 o0.0001
R0/R1 61 39 49
Abbreviations: CEA¼ carcinoembryonic antigen; CLM¼ colorectal liver metastases; Extrahep.¼extrahepatic; MRI¼magnetic resonance imaging; MS¼median survival; OS¼overall survival;
postop.¼postoperative; preop.¼preoperative.
BRITISH JOURNAL OF CANCER A LiverMetSurvey registry-based analysis
608 www.bjcancer.com |DOI:10.1038/bjc.2017.218
probability at 3 and 5 years decreased to 70–77% and 50–61% in
patients with three additional favourable factors, 58–68% and 35–
47% in patients with two additional favourable factors, 44–55%
and 21–32% in patients with one additional factor, and 33 and 12%
in patients with no additional positive factors (Table 4).
DISCUSSION
General considerations. The main finding of the current study is
that a 5-year OS and median survival of at least of 21% and 34
months can be achieved in patients withX10 CLM after complete
treatment of macroscopic liver disease in patients with at least a
single additional favourable factor: age o60 years; a maximal
tumour sizeo40mm; preoperative MRI; preoperative chemother-
apy; and adjuvant chemotherapy.
Although 10 liver metastases or more is a common presentation
at diagnosis, the low proportion of this group reported here (4.3%
of the cohort) indicates that (1) most centres consider such
number of CLM as a contraindication for resection and (2) patients
operated are highly selected. This also translates the fact that an
important number of CLM may compromise technical feasibility
of complete resection. Indeed, the proportion of patients withX10
CLM, finally unresected or with incomplete resection (27.2%)
demonstrates how challenging it is to achieve curative resection in
these patients
Preoperative chemotherapy. Resection in patients with disease
progression while on chemotherapy was anecdotal (3.7%). This is
in accordance with previous studies showing the importance of a
disease control before considering surgery in patients with
advanced liver disease (Adam et al, 2004a, b; Garufi et al, 2010).
Therefore, the present findings cannot be applied in patients with a
progressive metastatic disease. The interpretation of our results
should be made at the light of this prerequisite.
What are the conditions that may ensure an additional benefit
of surgery compared to chemotherapy alone?. Interestingly, the
median survival of patients with R2/no resection (27 months) was
similar to that reported in contemporary trials of chemotherapies
in patients with metastatic unresectable disease (Heinemann et al,
2014; Loupakis et al, 2014), whereas the survival of R0/R1 patients
(median survival 49 months) was by far better and close to survival
rates observed in resected patients with fewer CLM (Nordlinger
et al, 2013). This shows that even in patients with very advanced
disease, resection has the potential to improve patient outcome.
Interestingly, preoperative MRI emerged as a favourable
prognostic factor, independently of the other ‘oncological’ para-
meters. Given the superiority of MRI over CT scan for detecting
small nodules, especially after neoadjuvant chemotherapy
(Kulemann et al, 2011), a shift in the disease staging may be
advanced to explain this finding. Indeed, it is likely that some
patients, initially considered as ‘resectable’ based on CT scan, may
become ineligible for surgery after preoperative MRI. This results
in a more favourable tumour biology or less-advanced disease in
the subgroup of patients with preoperative MRI. We also may
hypothesised that the quality of resection, especially in patients at
high risk of very small tumour foci, such as the ones with X10
CLM may be improved after MRI.
According to our multivariate model, macroscopically complete
resection, alone (i.e., without additional favourable factors), is
associated with a median OS of 31 months and a 12% 5-year OS.
The addition of a single favourable factor to R0/R1 surgery was
associated with a 5-year OS of 21–32% and a MS of 34–42 months.
This suggests that surgical treatment (often complex and
potentially morbid given the extent of the liver disease) should
Table 3. Pooled estimates of multivariate analysis for overall
survival in patients with X10 CLM
Variables HR Lower CI Upper CI P
Max tumour size X40mm 1.49 1.09 2.03 0.02
Age X60 years 1.51 1.13 2.00 0.005
Preoperative MRI 0.65 0.47 0.89 0.007
R0/R1 resection 0.35 0.26 0.48 o0.0001
Adjuvant chemotherapy 0.73 0.55 0.98 0.04
Abbreviations: CI¼ confidence interval; CLM¼ colorectal liver metastases; HR¼ hazards
ratio; MRI¼magnetic resonance imaging.
Table 4. Survival probabilities according to prognostic factors combinations in patients with X10 CLM who underwent R0/R1
resection
R0/R1
resection
Preop.
MRI
Maximum tumour size
o40mm
Age o60
years
Adjuvant
chemotherapy
3-yr OS
(%)
5-yr OS
(%)
MS
(months)
þ þ þ þ þ 82 69 NR
þ  þ þ þ 74 57 NR
þ þ  þ þ 70 50 69
þ þ þ  þ 77 61 NR
þ þ þ þ  75 57 NR
þ þ þ   68 47 54
þ þ  þ  58 36 47
þ þ   þ 62 40 50
þ   þ þ 58 35 47
þ  þ  þ 67 47 54
þ  þ þ  64 43 51
þ þ    48 25 36
þ  þ   55 32 42
þ   þ  44 21 34
þ    þ 48 25 36
þ     33 12 31
Abbreviations: MRI¼magnetic resonance imaging; MS¼median survival; NR, not reached; OS¼overall survival; Preop.¼preoperative.
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be undertaken only in patients with at least a single additional
favourable factor.
Outcomes of patients with X10 CLM are hampered by a high
rate of relapse (74.6%). This argues in favour of routine post-
operative chemotherapy, an independent factor of improved OS.
Improvement in adjuvant therapy may warrant more favourable
results in this subgroup of patients at high risk of recurrence and
then should be further investigated. In this setting, hepatic arterial
infusion may be a valid option to control microscopic residual
disease as recently suggested. (Goe´re´ et al, 2013). However,
contrary to randomised studies, the design of the present study did
not allow to demonstrate the favourable impact of adjuvant
therapy on survival. As most of institutions would refer patients
withX10 CLM for adjuvant therapy, it is likely that the absence of
post-operative chemotherapy is likely to be due to adverse post-
operative events such as surgical complications or deterioration of
the general status.
Repeat hepatectomy or extrahepatic resection for patients with
recurrence is another way to improve the outcome of these patients
as demonstrated by the better survival of patients submitted to this
repeat surgery, compared to those submitted to a single surgical
procedure. Of course, this group consists of selected patients, with
favourable tumour biology. However, these good outcomes
emphasise the relevance of an aggressive onco-surgical approach.
R0/R1 resection. Here we grouped R0/R1 resection. This may be
surprising knowing that R0 resection must remain an oncological
goal in surgery of CLM. However, in patients with X10 CLM, R0
and R1 resection yield similar survival as this has been already
reported in patients with a large number of CLM (de Haas et al,
2008; Folprecht et al, 2014). The proportion of R1 resection
directly results of the high number of lesions, the frequent use of
RFA and the necessity to preserve vascular structures.
At least 10 CLM on imaging studies obviously represents an
advanced stage of the metastatic disease and it is likely that many
small tumour foci cannot be detected by imaging studies.
Therefore, the survival benefit offered by a macroscopically
complete surgery that cannot eradicate all microscopic tumours
of the liver questions in some extent the ‘only R0’ principle of
oncologic surgery. These so-called ‘macroscopically complete
resections’ could in fact be likened from an oncological point of
view to cytoreductive surgery advocated in ovarian cancers whose
prognosis correlates with tumour residual (Winter et al, 2008).
Limitations of the study. This analysis carries some limitations.
The study is retrospective, multicentric and as a result, may suffer
from different selection criteria and heterogeneity in patient
management (preoperative imaging studies and experience in
complex liver surgery) between centres. We acknowledge that
patients with at least 10 CLM represents a highly selected
population. For that reason, we cannot ascertain that similar
results may be observed in a less selected cohort. It would also have
been interesting to precisely investigate the impact of the overall
tumour burden but this would imply an accurate information of all
tumour foci (for example, the tumour size of all metastases at all
locations). Such data are not available in the registry. Unfortu-
nately, the impact of preoperative PET–CT, already emphasised
(Wiering et al, 2005), could not be evaluated due to lacking data.
However, these results offer the advantage to reflect the ‘true life’ of
resection in this setting, irrespective of the level of expertise of the
centre. Moreover, these results represent the largest series reported
to date of patients with such a number of CLM.
In conclusion, the long-term outcome of patients with 10 CLM
or more is obviously worse compared to patients exhibiting fewer
lesions, but surgery after effective chemotherapy remains the only
hope of prolonged survival, especially in selected patients for
whom complete resection could be performed. In fact, it is likely
that the ‘10 and more’ patients only represent the visible part of the
iceberg. The present results show that the number of CLM should
not be considered as contraindication to surgery per se and should
encourage oncologists and surgeons to extend the surgical
indications beyond commonly admitted boundaries.
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